Table 2.
Risk of AF for Different Lp(a) Levels: the ARIC Study 1996–2011
| IRa | Model 1b | Model 2c | Model 3d | |
|---|---|---|---|---|
| Lp(a) categoriese | ||||
| ≤10 mg/dL | 9.1 | Reference (1) | Reference (1) | Reference (1) |
| >10 to 20 mg/dL | 8.8 | 1.01 (0.86–1.20) | 1.04 (0.88–1.23) | 1.03 (0.87–1.22) |
| >20 to 30 mg/dL | 9.2 | 1.12 (0.90–1.40) | 1.13 (0.90–1.40) | 1.16 (0.93–1.45) |
| >30 to 50 mg/dL | 7.6 | 0.94 (0.76–1.16) | 0.93 (0.75–1.15) | 0.94 (0.76–1.16) |
| >50 mg/dL | 8.4 | 1.06 (0.90–1.26) | 1.02 (0.86–1.21) | 0.98 (0.82–1.17) |
| Log‐Lp(a)e | 1.01 (0.96–1.05) | 1.00 (0.96–1.05) | 0.99 (0.95–1.04) | |
Values are expressed as incidence rates (IRs) and hazard ratios (95% confidence intervals). AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; LP(a), lipoprotein(a).
IR per 1000 person‐years.
Model 1 includes: age, sex, and race‐center groups.
Model 2 includes: model 1+smoking, systolic blood pressure, diastolic blood pressure, treatment for hypertension, heart rate, height, body mass index, ECG left ventricular hypertrophy, PR interval, prevalent heart failure, coronary artery disease, and diabetes mellitus.
Model 3: model 2+low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, lipid‐lowering medication, and log‐transformed (Log) N–terminal pro‐B type natriuretic peptide.
3 Interactions of Lp(a) and AF by race and sex were P=0.11 and P=0.92 for Lp(a) categories and P=0.39 and P=0.38 for continuous Lp(a), respectively.